Novel genetically-humanized mouse model established to evaluate efficacy of therapeutic agents to human interleukin-6 receptor

Scientific Reports

Volumn 3, Issue , 2013, Pages

  Ueda, Otoya ^a   Tateishi, Hiromi ^b   Higuchi, Yoshinobu ^a   Fujii, Etsuko ^a   Kato, Atsuhiko ^a   Kawase, Yosuke ^b   Wada, Naoko A ^a,b   Tachibe, Takanori ^b   Kakefuda, Mami ^b   Goto, Chisato ^b   Kawaharada, Makoto ^b   Shimaoka, Shin ^a   Hattori, Kunihiro ^a   Jishage, Kou Ichi ^a  

^a CHUGAI PHARMACEUTICAL CO LTD   (Japan)

^b Chugai Research Institute for Medical Science Inc   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

INTERLEUKIN 6; INTERLEUKIN 6 RECEPTOR; MONOCLONAL ANTIBODY; TOCILIZUMAB;

ANGIOFOLLICULAR LYMPH NODE HYPERPLASIA; ANIMAL; ARTICLE; BLOOD; C57BL MOUSE; DISEASE MODEL; EVALUATION; FEMALE; GENE TARGETING; GENETICS; HUMAN; IMMUNOLOGY; METABOLISM; MOUSE; PATHOLOGY; TRANSGENIC MOUSE;

ANIMALS; ANTIBODIES, MONOCLONAL, HUMANIZED; DISEASE MODELS, ANIMAL; FEMALE; GENE KNOCK-IN TECHNIQUES; GIANT LYMPH NODE HYPERPLASIA; HUMANS; INTERLEUKIN-6; MICE; MICE, INBRED C57BL; MICE, TRANSGENIC; RECEPTORS, INTERLEUKIN-6;

MLCS; MLOWN;

EID: 84881455783     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep01196     Document Type: Article

References (34)

1. Loisel, S. et al. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment. Crit Rev Oncol Hematol. 62, 34-42 (2007).
2. Chapman, K., Pullen, N., Graham, M. & Ragan, I. Preclinical safety testing of monoclonal antibodies: the significance of species relevance. Nature Rev. Drud Discov. 6, 120-126 (2007).
3. Hansel, T. T., Kropshofer, H., Singer, T., Mitchell, J. A. &George, A. J. The safety and side effects of monoclonal antibodies. Nature Rev. Drug Discov. 9, 325-338 (2010).
4. Palestro, G., Turrini, F., Pagano, M. & Chiusa, L. Castleman's disease. Adv. Clin. Path. 3, 11-22 (1999).
5. Cronin, D. M. P. & Warnke, R. A. Castleman disease: an update on classification and the spectrum of associated lesions. Adv. Anat. Pathol. 16, 236-246 (2009).
6. Yoshizaki, K. et al. Pathogenic significance of interleukine-6 (IL-6/BSF-2) in Castleman's disease. Blood. 74, 1360-1367 (1989).
7. Kitamura, H. et al. Bone marrow neutrophilia and suppressed bone turnover in human interleukin-6 transgenic mice. Am. J. Pathol. 147, 1682-1692 (1995).
8. Katsume, A. et al. Anti-interleukin 6 (IL-6) receptor antibody suppresses Castleman's disease like symptoms emerged in IL-6 transgenic mice. Cytokine. 20, 304-311 (2002).
9. Peters, M. et al. The function of the soluble interleukin 6 (IL-6) receptor in vivo: sensitization of human soluble IL-6 receptor transgenic mice towards IL-6 and prolongation of the plasma half-life of IL-6. J Exp Med. 183, 1399-1406 (1996).
10. Udagawa, N. et al. Interleukin (IL)-6 induction of osteoclast differentiation depends on IL-6 receptors expressed on osteoblastic cells but not on osteoclast progenitors. J Exp Med. 182, 1461-1468 (1995).
11. Sato, K. et al. Reshaping a human antibody to inhibit the interleukin 6-dependent tumor cell growth. Cancer Res. 53, 851-856 (1993).
12. Jishage, K. et al. Role of Lkb1, the causative gene of Peutz-Jegher's syndrome, in embryogenesis and polyposis. Proc Natl Acad Sci U S A. 99, 8903-8908 (2002).
13. Nishimoto, N. et al. Humanized anti-interleukin-6 receptor antibody treatment of multicentric Castleman disease. Blood. 106, 2627-2632 (2005).
14. Nishimoto, N. et al. Mechanisms and pathologic significances in increase in serum interleukin-6 (IL-6) and soluble IL-6 receptor after administration of an anti-IL-6 receptor antibody, tocilizumab, in patients with rheumatoid arthritis and Castleman disease. Blood. 112, 3959-3969 (2008).
15. Galicia, J. C. et al. Polymorphisms in the IL-6 receptor (IL-6R) gene: strong evidence that serum levels of soluble IL-6R are genetically influenced. Genes Immun. 5, 513-516 (2004).
16. Jensen, L. E. & Whitehead, A. S. Regulation of serum amyloid A protein expression during the acute-phase response. Biochem. J. 334, 489-503 (1998).
17. Okazaki, M., Yamada, Y., Nishimoto, N., Yoshizaki, K. & Mihara, M. Characterization of anti-mouse interleukin-6 receptor antibody. Immunol Lett. 84, 231-240 (2002).
18. Jones, S. A., Horiuchi, S., Topley, N., Yamamoto, N. & Fuller, G. M. The soluble interleukin 6 receptor: mechanisms of production and implications in disease. FASEB J. 15, 43-58 (2001).
19. Kallen, K. J. The role of transsignaling via the agonistic soluble IL-6 receptor in human diseases. Biochim Biophys Acta. 1592, 323-343 (2002).
20. Peters, M. et al. Extramedullary expansion of hematopoietic progenitor cells in interleukin (IL)-6-sIL-6R double transgenic mice. J Exp Med. 185, 755-766 (1997).
21. Niwa, H., Yamamura, K. & Miyazaki, J. Efficient selection for high-expression transfectants with a novel eukaryotic vector. Gene. 108, 193-199 (1991).
22. Horita, H., Yoshida, K., Kishimoto, T. & Taga, T. Continuous activation of gp130, a signal-transducing receptor component for interleukin 6-related cytokines, causes myocardial hypertrophy in mice. Proc Natl Acad Sci U S A. 92, 4862-4866 (1995).
23. Ehlers, M. et al. Identification of two novel regions of human IL-6 responsible for receptor binding and signal transduction. J Immunol. 153, 1744-1753 (1994).
24. Poli, V. et al. Interleukin-6 deficient mice are protected from bone loss caused by estrogen depletion. EMBO J. 13, 1189-1196 (1994).
25. Wunderlich, F. T. et al. Interleukin-6 signaling in liver-parenchymal cells suppresses hepatic inflammation and improves systemic insulin action. Cell Metab. 12, 237-249 (2010).
26. Jones, G. W. et al. Loss of CD4+ T cell IL-6R expression during inflammation underlines a role for IL-6 trans signaling in the local maintenance of Th17 cells. J Immunol. 184, 2130-2139 (2010).
27. McFarland-Mancini, M. M. et al. Differences in wound healing in mice with deficiency of IL-6 versus IL-6 receptor. J Immunol. 184, 7219-7228 (2010).
28. Igawa, T. et al. Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization. Nat Biotechnol. 28, 1203-1207 (2010).
29. Yoshida, H., Hashizume, M., Suzuki, M. & Mihara, M. Induction of high-dose tolerance to the rat anti-mouse IL-6 receptor antibody in NZB/NZW F1 mice. Rheumatol Int. 31, 1445-1449 (2011).
30. Sakurai, T. et al. The Effects of Interleukin-6 Signal Blockade on Fertility, Embryofetal Development, and Immunization In vivo. Birth Defects Res B Dev Reprod Toxicol. 95, 304-317 (2012).
31. Nishimoto, N. & Kishimoto, T. Interleukin 6: from bench to bedside. Nat Clin Pract Rheumatol. 2, 619-626 (2006).
32. Kurihara, Y. et al. Elevated blood pressure and craniofacial abnormalities in mice deficient in endothelin-1. Nature 368, 703-710 (1994).
33. Suzuki, H. et al. A role for macrophage scavenger receptors in atherosclerosis and susceptibility to infection. Nature 386, 292-296 (1997).
34. +/- mice. Am J Physiol Renal Physiol. 301, F1105-1113 (2011).